Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same author

Spectrum of Dystonia in Spinocerebellar Ataxia.

Tremor and other hyperkinetic movements (New York, N.Y.)·2026
Same author

Dystonia and Tremor.

Seminars in neurology·2026
Same author

Understanding Sociocultural Factors Shaping Married Men's Vasectomy Decisions: A Qualitative Study in Bihar.

Cureus·2026
Same author

Tremor.

Seminars in neurology·2026
Same author

Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis.

Nature communications·2026
Same journal

Indian Expert Consensus on Allergic Rhinitis in Women: A Modified Delphi Survey.

The Journal of the Association of Physicians of India·2026
Same journal

Systematic Review of Topical Capsaicin 0.075% for the Treatment of Neuropathic Pain: Efficacy, Safety, and Tolerability.

The Journal of the Association of Physicians of India·2026
Same journal

Sodium-Glucose Cotransporter 2 Inhibitors in Kidney Diseases Other Than That Due to Diabetes: Benefits in Composite Renal Outcomes Driven by Immunoglobulin A Nephropathy.

The Journal of the Association of Physicians of India·2026
Same journal

<i>Fasciolopsis buski</i> Diagnosed by Upper Gastrointestinal Endoscopy.

The Journal of the Association of Physicians of India·2026
Same journal

"Academic Overdose" among Healthcare Professionals.

The Journal of the Association of Physicians of India·2026
Same journal

Respiratory Examination for Postgraduate Residents: Unrevealing Expert's Questions and Answers.

The Journal of the Association of Physicians of India·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model
07:32

Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model

Published on: December 28, 2021

Parkinson's disease: recent advances.

Sanjay Pandey1

  • 1Department of Neurology, GB Pant Hospital, Delhi.

The Journal of the Association of Physicians of India
|February 16, 2013
PubMed
Summary
This summary is machine-generated.

Parkinson's disease is a common neurodegenerative disorder, typically diagnosed clinically and often beginning in the sixth decade. Effective treatments like dopa agonists and L-dopa exist, but managing motor fluctuations remains a challenge.

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Experiment Videos

Last Updated: May 14, 2026

Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model
07:32

Locomotor Assessment of 6-Hydroxydopamine-induced Adult Zebrafish-based Parkinson's Disease Model

Published on: December 28, 2021

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Area of Science:

  • Neurology
  • Neurodegenerative Disorders

Background:

  • Parkinson's disease is a prevalent neurodegenerative disorder.
  • Diagnosis is primarily clinical, though familial forms are increasingly recognized.
  • Symptom onset commonly occurs in the sixth decade of life.

Purpose of the Study:

  • To review the clinical diagnosis and management of Parkinson's disease.
  • To discuss first-line treatment options including dopa agonists and L-dopa.
  • To highlight challenges in long-term Parkinson's disease management.

Main Methods:

  • Clinical review of Parkinson's disease diagnosis.
  • Discussion of pharmacological treatment strategies.
  • Analysis of long-term management challenges.

Main Results:

  • Parkinson's disease diagnosis is predominantly clinical.
  • Dopa agonists and L-dopa provide good initial responses.
  • Motor fluctuations, including wearing off and dyskinesias, present significant long-term management issues.

Conclusions:

  • Clinical diagnosis is standard for Parkinson's disease.
  • Pharmacological interventions offer symptomatic relief.
  • Addressing motor complications is crucial for sustained patient well-being.